CAT upholds infringement decision for pay for delay pharma deals

 CMA, here. 

U.S. Court of Appeals for the Fifth Circuit Upholds FTC’s Opinion against Generic Pharmaceutical Company Impax Laboratories, LLC

 FTC, here. 

Brief Amici Curiae of 82 Law, Economics, Business, and Medical Professors in Support of Respondent

M. Carrieret al., here. 

Patent Settlements in the Pharmaceutical Industry: What Can We Learn From Economic Analysis?

W. Kerber, S. Frank, here. 

California Supreme Court Takes Up 'Pay for Delay' Settlements

TheRecorder, here. 

The Technology Transfer Block Exemption

Out-law.com, here. 

European Pharmaceutical Antitrust after Groupment des Cartes Bancaires – Time to Rethink the Approach to Pay For Delay Settlements?

S. Gallasch, here. 

The EU Commission Decision against Servier – a New Dimension to European Pharmaceutical Antitrust?

S. Gallasch, here. 

Competition Policy and the Technologies of Information

H. Hovenkamp, here.

Competition law, intellectual property rights and dynamic analysis: Towards a new institutional “equilibrium ?”

F. Jenny, I. Lianos, H. Hovenkamp. F. Marshall, S. Sivaramjani Thambisetty, here.

Chapters, in detail:

I. Lianos, Introduction
S. Thamisetty, WHY PATENT LAW DOESN’T DO INNOVATION POLICY
H. Hovenkamp, INSTITUTIONAL ADVANTAGE IN COMPETITION AND INNOVATION POLICY
F. Jenny, ANTICOMPETITIVE ABUSES OF PATENT SYSTEMS AND THE ROLE OF COMPETITION AUTHORITIES
F. Marshall, A STUDY OF EXECUTIVE BRANCH COLLABORATION

Pay-to-Delay Settlements: The Circuit-Splitting Headache Plaguing Big Pharma

S. Han, here. 

Economic Analysis of Pay-for-Delay Settlements and Their Legal Ruling

L. Gratz, here.